What is the treatment for polymorphous light eruption?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The treatment for polymorphous light eruption (PMLE) should prioritize prevention and symptom management, with phototherapy, specifically PUVA, considered if UVB has failed or is not suitable, as recommended by the British Association of Dermatologists and British Photodermatology Group guidelines 1. The first-line approach involves sun protection measures including wearing protective clothing, applying broad-spectrum sunscreen (SPF 30+), and avoiding peak sun exposure hours. For mild symptoms, topical corticosteroids like hydrocortisone 1% or triamcinolone 0.1% can be applied to affected areas 2-3 times daily until symptoms resolve. Oral antihistamines such as cetirizine 10mg daily or diphenhydramine 25-50mg every 6 hours can help reduce itching. Some key points to consider in the management of PMLE include:

  • The risk of provoking PLE is high, particularly with the first few PUVA exposures, and can be managed with potent topical steroid and subsequent lower dose increments 1.
  • Post-treatment advice generally includes continued natural sunlight exposure, ranging from 2 h weekly to ‘cautious exposure, with sunscreens for extended outdoor stay’ to ‘expose freely to sun’ 1.
  • PUVA should be considered before other systemic treatments, and the treatment should be carried out with full knowledge of the patient’s action spectrum, in a specialist unit experienced in managing this disease 1. In severe or recurrent cases, systemic treatments may be necessary, including short courses of oral prednisone or prophylactic antimalarials like hydroxychloroquine, as well as beta-carotene supplements to increase skin tolerance to light 1.

From the Research

Treatment Options for Polymorphous Light Eruption

The treatment for polymorphous light eruption (PLE) includes several options, such as:

  • Sun protection: using sunscreens with high protection levels against UVB and UVA radiation 2
  • Corticosteroids: to reduce inflammation and prevent the eruption 3
  • Desensitization phototherapy: to increase the skin's tolerance to sunlight 3
  • Anti-inflammatory and immunomodulatory agents: to reduce the immune response and prevent the eruption 3
  • Oral photochemotherapy (PUVA): to prevent the eruption, especially in cases of UVA-induced PLE 4, 5
  • Topical formulations: containing antioxidants and UVA-protective agents, such as alpha-glucosylrutin and tocopheryl acetate, to prevent the eruption 6

Prevention of Polymorphous Light Eruption

Prevention of PLE can be achieved through:

  • Using sunscreens with high protection levels against UVB and UVA radiation 2
  • Wearing protective clothing and seeking shade when outdoors 2
  • Undergoing desensitization phototherapy to increase the skin's tolerance to sunlight 3
  • Applying topical formulations containing antioxidants and UVA-protective agents 6

Action Spectrum and Photoprotection

The action spectrum of PLE can be either UVA, UVB, or both, and photoprotection can be achieved through the use of sunscreens and protective clothing 5

  • UVA-induced PLE: oral photochemotherapy (PUVA) is an effective preventive treatment 4, 5
  • UVB-induced PLE: topical sunscreens can be sufficient to protect against the eruption 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Treatment of polymorphic light eruption.

Photodermatology, photoimmunology & photomedicine, 2003

Research

Treatment of polymorphous light eruption.

Archives of dermatological research.., 1983

Research

Polymorphous light eruption: action spectrum and photoprotection.

Journal of the American Academy of Dermatology, 1986

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.